SEC Form 4 · accession 0001140361-17-034333
Emergent BioSolutions Inc. · EBS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Daniel Abdun-Nabi
Officer — President & CEO · Director
Period of report
Aug 31, 2017
Accepted (ET)
Sep 5, 2017 · 5:16 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001367644
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Aug 31, 2017 | M | 15,000 | $22.03 | A | 219,134 | D | |
| Common StockF1,F2 | Aug 31, 2017 | S | 15,000 | $37.21 | D | 204,134 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F3,F4 | $22.03 | Aug 31, 2017 | M | 15,000 | D | — | Mar 14, 2018 | Common Stock | 15,000 | 26,508 | D |
Explanation of responses
- F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Abdun-Nabi.
- F2The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.14 to $37.27, inclusive.
- F3Consists of an option granted under the company's stock incentive plan as amended and restated.
- F4The option grant vests in three equal installments on the day prior to the first, second and third anniversary dates of the grant.